Decreased Azithromycin Susceptibility of Neisseria gonorrhoeae Isolates in Patients Recently Treated with Azithromycin

Clinical Infectious Diseases

Volumn 65, Issue 1, 2017, Pages 37-45

  Wind, Carolien M ^a   De Vries, Esther ^a   Schim Van Der Loeff, Maarten F ^b,d   Van Rooijen, Martijn S ^a   Van Dam, Alje P ^a,c   Demczuk, Walter H B ^f   Martin, Irene ^f   De Vries, Henry J C ^a,e  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b Research Department   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis General Hospital   (Netherlands)

^d Department of General Medicine ^*  (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

antimicrobial resistance; azithromycin; Neisseria gonorrhoeae; treatment; whole genome sequencing

Indexed keywords

AZITHROMYCIN; MOLECULAR MARKER; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; ETHNICITY; FEMALE; GONORRHEA; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; MUTATION; NEISSERIA GONORRHOEAE; PHYLOGENY; PRESCRIPTION; PRIORITY JOURNAL; WHOLE GENOME SEQUENCING; ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; DRUG EFFECT; GENETICS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; RETROSPECTIVE STUDY;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOME, BACTERIAL; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; NEISSERIA GONORRHOEAE; RETROSPECTIVE STUDIES;

EID: 85021841695     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix249     Document Type: Article

References (22)

1. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1-137.
2. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24:85-92.
3. Chisholm SA, Wilson J, Alexander S, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sex Transm Infect 2016; 92:365-7.
4. Fifer H, Natarajan U, Jones L, et al. Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 2016; 374:2504-6.
5. Brunner A, Nemes-Nikodem E, Jeney C, et al. Emerging azithromycin-resistance among the Neisseria gonorrhoeae strains isolated in Hungary. Ann Clin Microbiol Antimicrob 2016; 15:53.
6. Horner P, Saunders J. Should azithromycin 1 g be abandoned as a treatment for bacterial STIs The case for and against. Sex Transm Infect 2017; 93:85-7.
7. Lanjouw E, Ouburg S, de Vries HJ, Stary A, Radcliffe K, Unemo M. 2015 European guideline on the management of Chlamydia trachomatis infections. Int J STD AIDS 2016; 27:333-48.
8. Horner P, Blee K, O'Mahony C, et al. 2015 UK national guideline on the management of non-gonococcal urethritis. Int J STD AIDS 2016; 27:85-96.
9. World Health Organization. WHO guidelines for the treatment of Chlamydia trachomatis. Geneva: WHO, 2016.
10. World Health Organization. WHO guidelines for the treatment of Neisseria gonorrhoeae. Geneva: WHO, 2016.
11. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-A cquired pneumonia in adults. Clin Infect Dis 2007; 44, Suppl 2:S27-72.
12. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279-82.
13. Demczuk W, Lynch T, Martin I, et al. Whole-genome phylogenomic heterogeneity of Neisseria gonorrhoeae isolates with decreased cephalosporin susceptibility collected in Canada between 1989 and 2013. J Clin Microbiol 2015; 53:191-200.
14. Demczuk W, Martin I, Peterson S, et al. Genomic epidemiology and molecular resistance mechanisms of azithromycin-resistant Neisseria gonorrhoeae in Canada from 1997 to 2014. J Clin Microbiol 2016; 54:1304-13.
15. Martin IM, Ison CA, Aanensen DM, Fenton KA, Spratt BG. Rapid sequencebased identification of gonococcal transmission clusters in a large metropolitan area. J Infect Dis 2004; 189:1497-505.
16. Young H, Moyes A, McMillan A. Azithromycin and erythromycin resistant Neisseria gonorrhoeae following treatment with azithromycin. Int J STD AIDS 1997; 8:299-302.
17. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012; 39:877-9.
18. Ng LK, Martin I, Liu G, Bryden L. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother 2002; 46:3020-5.
19. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother 2010; 54:3812-6.
20. King A, Bathgate T, Phillips I. Erythromycin susceptibility of viridans streptococci from the normal throat flora of patients treated with azithromycin or clarithromycin. Clin Microbiol Infect 2002; 8:85-92.
21. Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners. PLoS Pathog 2016; 12:e1005611.
22. Kenyon CR, Osbak K, Vandenbruane M. What is the appropriate therapy for asymptomatic gonorrhoea in men who have sex with men Int J STD AIDS 2016; 27:812-3.